Literature DB >> 18400800

The relationship between leishmaniasis and AIDS: the second 10 years.

Jorge Alvar1, Pilar Aparicio, Abraham Aseffa, Margriet Den Boer, Carmen Cañavate, Jean-Pierre Dedet, Luigi Gradoni, Rachel Ter Horst, Rogelio López-Vélez, Javier Moreno.   

Abstract

To date, most Leishmania and human immunodeficiency virus (HIV) coinfection cases reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of coinfection were identified, of which 90% were from Spain, Italy, France, and Portugal. However, these figures are misleading because they do not account for the large proportion of cases in many African and Asian countries that are missed due to a lack of diagnostic facilities and poor reporting systems. Most cases of coinfection in the Americas are reported in Brazil, where the incidence of leishmaniasis has spread in recent years due to overlap with major areas of HIV transmission. In some areas of Africa, the number of coinfection cases has increased dramatically due to social phenomena such as mass migration and wars. In northwest Ethiopia, up to 30% of all visceral leishmaniasis patients are also infected with HIV. In Asia, coinfections are increasingly being reported in India, which also has the highest global burden of leishmaniasis and a high rate of resistance to antimonial drugs. Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400800      PMCID: PMC2292576          DOI: 10.1128/CMR.00061-07

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  275 in total

1.  Leishmania major and HIV co-infection in Burkina Faso.

Authors:  Robert T Guiguemdé; Oumar S Sawadogo; Christian Bories; Kadidiatou L Traore; Désiré Nezien; Laetitia Nikiema; Francine Pratlong; Pierre Marty; René Houin; Michéle Deniau
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 Mar-Apr       Impact factor: 2.184

Review 2.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors.

Authors:  Karl Schenkel; Suman Rijal; Siddhartha Koirala; Shekhar Koirala; Veerle Vanlerberghe; Patrick Van der Stuyft; Marina Gramiccia; Marleen Boelaert
Journal:  Trop Med Int Health       Date:  2006-12       Impact factor: 2.622

4.  Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up.

Authors:  C Riera; R Fisa; P Lopez; E Ribera; J Carrió; V Falcó; I Molina; M Gállego; M Portús
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

5.  Uncommon clinical presentations of cutaneous leishmaniasis in Sudan.

Authors:  E M Elamin; S Guerbouj; A M Musa; I Guizani; E A G Khalil; M M Mukhtar; A M Y Elkadaro; H S Mohamed; M E Ibrahim; M M Abdel Hamid; M El Azhari; A M El Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-11       Impact factor: 2.184

Review 6.  Immunological phenomena in leprosy and related diseases.

Authors:  J L Turk; A D Bryceson
Journal:  Adv Immunol       Date:  1971       Impact factor: 3.543

7.  [Concurrent leishmaniasis and human immunodeficiency virus (HIV) infection: a study of four cases].

Authors:  A S Borges; A A Machado; M S Ferreira; J F de Castro Figueiredo; G F Silva; S Cimerman; H A Bacha; M C Teixeira
Journal:  Rev Soc Bras Med Trop       Date:  1999 Nov-Dec       Impact factor: 1.581

8.  The identification and variability of the parasites causing leishmaniasis in HIV-positive patients in Italy.

Authors:  M Gramiccia
Journal:  Ann Trop Med Parasitol       Date:  2003-10

9.  Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis.

Authors:  A Barral; R Badaró; M Barral-Netto; G Grimaldi; H Momem; E M Carvalho
Journal:  Am J Trop Med Hyg       Date:  1986-07       Impact factor: 2.345

10.  Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.

Authors:  Herbert Sindermann; Kirsten R Engel; Christina Fischer; Wolfgang Bommer
Journal:  Clin Infect Dis       Date:  2004-10-18       Impact factor: 9.079

View more
  288 in total

1.  Disseminated cutaneous leishmaniasis resembling post-kala-azar dermal leishmaniasis caused by Leishmania donovani in three patients co-infected with visceral leishmaniasis and human immunodeficiency virus/acquired immunodeficiency syndrome in Ethiopia.

Authors:  Tesfaye Gelanew; Zewdu Hurissa; Ermias Diro; Aysheshm Kassahun; Katrin Kuhls; Gabriele Schönian; Asrat Hailu
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Leishmaniasis in the United States: treatment in 2012.

Authors:  Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

3.  Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment.

Authors:  Albrecht Stenzinger; Johannes Nemeth; Frederick Klauschen; Christiane Schewe; Axel-Michael Ladhoff; Alexander Muckenhuber; Mariana Schürmann; Dirk Schürmann; Wilko Weichert
Journal:  Virchows Arch       Date:  2012-02-16       Impact factor: 4.064

4.  Arboprotozoae.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

5.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

6.  Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.

Authors:  Johan van Griensven; Tesfa Simegn; Mengistu Endris; Ermias Diro
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

Review 7.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

8.  Changing epidemiology of visceral leishmaniasis in northeastern Brazil: a 25-year follow-up of an urban outbreak.

Authors:  Ádila L M Lima; Iraci D de Lima; José F V Coutinho; Úrsula P S T de Sousa; Marcos A G Rodrigues; Mary E Wilson; Richard D Pearson; José W Queiroz; Selma M B Jerônimo
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-10-01       Impact factor: 2.184

Review 9.  Elimination of visceral leishmaniasis on the Indian subcontinent.

Authors:  Om Prakash Singh; Epco Hasker; Marleen Boelaert; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2016-09-28       Impact factor: 25.071

10.  Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.

Authors:  Cristiana T Trinconi; Juliana Q Reimão; Jenicer K U Yokoyama-Yasunaka; Danilo C Miguel; Silvia R B Uliana
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.